Closed-loop insulin delivery improves blood sugar control in type 1 diabetes

A study presented at this year’s annual meeting of the European Association for the Study of Diabetes has shown that hybrid day-night closed-loop insulin delivery systems are more effective at controlling blood sugar levels in type 1 diabetes than sensor-augmented pump therapy.

By Magic mineImage Credit: Magic mine / Shutterstock

With sensor-augmented pump therapy, an insulin pump is combined with a continuous glucose monitoring sensor that sends readings to the patient who is then responsible for administering their insulin doses.

Closed-loop insulin delivery systems, on the other hand, combine this monitoring with an insulin pump and an algorithm that enables automatic insulin delivery.

Hybrid closed-loop systems combine automated delivery with insulin delivery initiated by the patient. The first of these systems was introduced into clinical practice in 2017 following a safety trial.

For the study, 86 patients with type 1 diabetes (aged six years and older) treated with insulin pump therapy and who had sub-optimal blood glucose control, were randomly assigned to receive either sensor-augmented pump therapy (control group) or the hybrid closed-loop therapy over a 12 -week period.

The participants underwent training on the insulin pump and glucose monitoring during a 4-week run-in period.

As reported in The Lancet, glucose levels were within the target range of 3.9 to 10.0mmol/L for a significantly greater proportion of time in the closed-loop group compared with the control group, at 65% versus 54%.

In the closed-loop group, the HbA1c level fell from 8.3% to 8.0% after training and to 7.4% after the study.

The corresponding figures in the control group were 8.2%, 7.8%, and 7.7%. This difference in reduction was a significant 0.36%.

The median amount of time spent in a hypoglycemic state (glucose below 3.9mmol/L) was 12 minutes lower in the closed-loop group versus control group and the time spent in a hyperglycemic state (above 10.0mmol/L) was 2 hours and 24 minutes lower.

Overall, the proportion of time spent in the hypo-or hyperglycemic state in the closed-loop group was a median of 3.5% at baseline and 2.6% after the study.

The corresponding figures for the controls were 3.3% and 3.9%.

The authors conclude that, compared with sensor-augmented pump therapy, the use of day-and night-hybrid closed-loop insulin delivery improves glycemic control in people with type 1 diabetes and reduces their risk of hypoglycemia.

Results from our study together with those from previous studies support the adoption of closed-loop technology in clinical practice across all age groups."

Sally Robertson

Written by

Sally Robertson

Sally has a Bachelor's Degree in Biomedical Sciences (B.Sc.). She is a specialist in reviewing and summarising the latest findings across all areas of medicine covered in major, high-impact, world-leading international medical journals, international press conferences and bulletins from governmental agencies and regulatory bodies. At News-Medical, Sally generates daily news features, life science articles and interview coverage.



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment